CoChat

Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study

Open access
Tartof, Sara Y., Slezak, Jeff M., Puzniak, Laura, Hong, Vennis, Frankland, Timothy B., Ackerson, Bradley K., Takhar, Harpreet S., Ogun, Oluwaseye A., Simmons, Sarah R., Zamparo, Joann M., Gray, Sharon, Valluri, Srinivas R., Pan, Kaije, Jodar, Luis, McLaughlin, John M. · 2022 · The Lancet Regional Health - Americas
Cited by 108

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Background: Globally, recommendations are expanding for third (booster) doses of BNT162b2. In the United States, as of November 19, 2021, boosters were recommended for all adults aged 18 years and older. We evaluated the effectiveness of a third dose of BNT162b2 among adults in a large US integrated health system.Methods: In this retrospective cohort study, we analyzed electronic health records from Kaiser Permanente Southern California between Dec 14, 2020 and Dec 5, 2021 to assess vaccine effectiveness (VE) of two and three doses of BNT162b2 against SARS-CoV-2 infections and COVID-19-related hospital admission. VE was calculated using hazards ratios from adjusted Cox models.Findings: After only two doses, VE against infection declined from 85% (95% CI 83–86) during the first month to 49% (46–51) seven to eight months following vaccination. Overall VE against hospitalization was 90% (95% CI 86–92) within one month and did not wane, however, effectiveness against hospitalization appeared to wane among immunocompromised individuals. Three-dose VE was 88% (95% CI 86–89) against infection and 97% (95–98) against hospitalization. Effectiveness after three doses was higher than that seen one month after receiving only two doses for both outcomes. Relative VE of three doses compared to two (with at least six months after the second dose) was 75% (95% CI 71−78) and 70% (48−83) against infections and hospital admissions, respectively.Interpretation: These data support the benefit of broad BNT162b2 booster recommendations, as three doses confers comparable, if not better, protection against SARS-CoV-2 infections and hospital admission as was seen soon after receiving two doses.Trial Registration: This study was registered with: NCT04848584. Funding: Pfizer Inc.Declaration of Interest: JMZ, SG, SRV, KP, LJ, LP, and JMM are employees of and hold stock and/or stock options in Pfizer Inc. TBF holds stock in Pfizer Inc. SYT, JMS, VH, BA, HT, TF, SRS, and OO received research support from Pfizer during the conduct of this study that was paid directly to KPSC. All other authors report no conflicts.Ethical Approval: The study protocol was reviewed and approved by the KPSC institutional review board which waived requirement for informed consent (number 12816).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.lana.2022.100198

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 108

Metadata

Authors
Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V., Frankland, T. B., Ackerson, B. K., Takhar, H. S., Ogun, O. A., Simmons, S. R., Zamparo, J. M., Gray, S., Valluri, S. R., Pan, K., Jodar, L., & McLaughlin, J. M.
Venue
The Lancet Regional Health - Americas
Publisher
Elsevier BV
Published
2022-05
Volume
9
Pages
100198
ISSN
2667-193X (ISSN-L)
OpenAlex
W4225272130
Cited by
108
References
24
FWCI
6.96
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study. https://app.cochat.ai/papers/10.1016/j.lana.2022.100198
The paper
Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V., Frankland, T. B., Ackerson, B. K., Takhar, H. S., Ogun, O. A., Simmons, S. R., Zamparo, J. M., Gray, S., Valluri, S. R., Pan, K., Jodar, L., & McLaughlin, J. M. (2022). Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study. The Lancet Regional Health - Americas. https://doi.org/10.1016/j.lana.2022.100198

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.